Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Trevi Therapeutics Inc
TRVICurrent price
6.19 USD
-0.02 USD (-0.32%)
Last closed
6.19 USD
Company
www.trevitherapeutics.com
ISIN
US89532M1018
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
675 808 768 USD
Yield for 12 month
+117.96 %
1Y
3Y
5Y
10Y
15Y
TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is based in New Haven, Connecticut. Address: 195 Church Street, New Haven, CT, United States, 06510
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
19.83 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-123 000 USD
Current Quarter
–
Last Quarter
–
Key Figures TRVI
1 year
3 years
5 years
10 years
EBITDA
-51 377 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-32.15 %
PEG Ratio
–
Return On Equity TTM
-52.59 %
Wall Street Target Price
19.83 USD
Revenue TTM
–
Book Value
1.07 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.47 USD
Diluted Eps TTM
-0.47 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics TRVI
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History TRVI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation TRVI
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-4.92
Price Book MRQ
6.78
Financials TRVI
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TRVI
For 52 weeks
2.30 USD
7.39 USD
50 Day MA
5.91 USD
Shares Short Prior Month
5 503 093
200 Day MA
3.98 USD
Short Ratio
3.36
Shares Short
5 911 171
Short Percent
8.53 %
BeatStart